Rhumbline Advisers Biogen Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Biogen Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 284,206 shares of BIIB stock, worth $49.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

284,206

Previous 278,644 2.0%

Holding current value

$49.4 Million

Previous $60.1 Million 9.65%

% of portfolio

0.06%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$190.52 - $236.72 $1.06 Million - $1.32 Million	5,562 Added 2.0%	284,206 $65.9 Million
Q1 2024 May 09, 2024	BUY	$212.02 - $267.71 $126,575 - $159,822	597 Added 0.21%	278,644 $60.1 Million
Q4 2023 Feb 08, 2024	SELL	$222.59 - $267.94 $112,407 - $135,309	-505 Reduced 0.18%	278,047 $72 Million
Q3 2023 Nov 09, 2023	SELL	$253.3 - $285.89 $553,207 - $624,383	-2,184 Reduced 0.78%	278,552 $71.6 Million
Q2 2023 Aug 08, 2023	BUY	$275.25 - $318.06 $263,139 - $304,065	956 Added 0.34%	280,736 $80 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $301,458 - $343,499	1,175 Added 0.42%	279,780 $77.8 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $1.35 Million - $1.64 Million	5,359 Added 1.96%	278,605 $77.2 Million
Q3 2022 Nov 10, 2022	BUY	$194.69 - $268.46 $1.96 Million - $2.71 Million	10,082 Added 3.83%	273,246 $73 Million
Q2 2022 Aug 11, 2022	BUY	$187.54 - $223.02 $2.29 Million - $2.72 Million	12,204 Added 4.86%	263,164 $53.7 Million
Q1 2022 May 12, 2022	SELL	$193.77 - $244.14 $4.41 Million - $5.55 Million	-22,739 Reduced 8.31%	250,960 $52.9 Million
Q4 2021 Feb 10, 2022	BUY	$223.92 - $287.77 $955,242 - $1.23 Million	4,266 Added 1.58%	273,699 $65.7 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $1.39 Million - $1.81 Million	-4,906 Reduced 1.79%	269,433 $76.2 Million
Q2 2021 Aug 05, 2021	SELL	$259.0 - $414.71 $5.07 Million - $8.12 Million	-19,578 Reduced 6.66%	274,339 $95 Million
Q1 2021 May 06, 2021	SELL	$242.95 - $284.63 $3.78 Million - $4.43 Million	-15,559 Reduced 5.03%	293,917 $82.2 Million
Q4 2020 Feb 10, 2021	SELL	$236.26 - $355.63 $10.2 Million - $15.4 Million	-43,308 Reduced 12.28%	309,476 $75.8 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $1.17 Million - $1.35 Million	-4,405 Reduced 1.23%	352,784 $100 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $432,479 - $572,743	1,672 Added 0.47%	357,189 $95.6 Million
Q1 2020 May 06, 2020	BUY	$268.85 - $341.04 $1.03 Million - $1.3 Million	3,818 Added 1.09%	355,517 $112 Million
Q4 2019 Feb 05, 2020	SELL	$220.06 - $304.07 $451,563 - $623,951	-2,052 Reduced 0.58%	351,699 $104 Million
Q3 2019 Oct 23, 2019	SELL	$217.44 - $243.88 $713,638 - $800,414	-3,282 Reduced 0.92%	353,751 $82.4 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $4.59 Million - $5.06 Million	20,925 Added 6.23%	357,033 $83.5 Million
Q1 2019 May 01, 2019	BUY	$216.71 - $338.96 $2.48 Million - $3.88 Million	11,441 Added 3.52%	336,108 $79.4 Million
Q4 2018 Jan 31, 2019	SELL	$278.5 - $352.75 $407,724 - $516,426	-1,464 Reduced 0.45%	324,667 $97.7 Million
Q3 2018 Nov 07, 2018	SELL	$293.51 - $383.83 $5.61 Million - $7.34 Million	-19,129 Reduced 5.54%	326,131 $115 Million
Q2 2018 Aug 06, 2018	BUY	$257.52 - $306.91 $1.48 Million - $1.77 Million	5,754 Added 1.69%	345,260 $100 Million
Q1 2018 May 02, 2018	SELL	$260.13 - $367.91 $1.81 Million - $2.56 Million	-6,966 Reduced 2.01%	339,506 $93 Million
Q4 2017 Feb 09, 2018	BUY	$307.64 - $344.58 $2.27 Million - $2.55 Million	7,395 Added 2.18%	346,472 $110 Million
Q3 2017 Nov 06, 2017	BUY	$281.15 - $329.69 $95.3 Million - $112 Million	339,077	339,077 $106 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Biogen Inc. Transaction History